LHRH-antagonists in the treatment of fertility disorders

US7393834B2 · kind B2 · utility

Assignee

• Aeterna Zentaris, Inc. · DE

Inventors

• Philippe Bouchard · Paris, FR
• Rene Frydman · Paris, FR
• Paul Devroey · Aalst, BE
• Klaus Diedrich · Gladbeck, DE
• Jurgen Engel · Alzenau, DE

Key dates

• Filing date: Sep 15, 2003
• Grant date: Jul 1, 2008
• Expiry date: May 17, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12M21/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.